Physician profile
Bradley E Manin
NPI 1932105368
$2,854.18
in general payments reported to CMS, 2019-2025
27 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $74.31 · 2021: $42.88 · 2022: $212 · 2023: $716 · 2024: $484 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,235.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $431.30 | 2019-2025 | Wegovy |
| Abbott Laboratories | $317.15 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $251.82 | 2023-2025 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $211.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $201.71 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $163.18 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $161.71 | 2023-2025 | |
| Astellas Pharma US INC | $137.83 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $135.79 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.81 | 2019-2025 | Jardiance, Synjardy |
| Gilead Sciences, INC. | $93.12 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $93.06 | 2019-2025 | Spravato |
| Dexcom, INC. | $85.61 | 2021-2024 | Dexcom G6 Transmitter |
| Stryker Corporation | $69.27 | 2023 | Xpress Ent Dilation System |
| Amgen INC. | $59.73 | 2019-2025 | Evenity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $51.41 | 2022 | |
| Viiv Healthcare Company | $45.42 | 2025 | Apretude |
| Inspire Medical Systems, INC. | $38.03 | 2023-2025 | Inspire |
| Currax Pharmaceuticals LLC | $32.64 | 2022 | |
| Merck Sharp & Dohme LLC | $30.30 | 2019 | |
| Bausch Health US, LLC | $24.56 | 2025 | Wellbutrin |
| Dynavax Technologies Corporation | $21.83 | 2023 | Heplisav-B |
| Janssen Biotech, INC. | $19.76 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.39 | 2021 | |
| Sanofi Pasteur INC. | $15.58 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.08 | 2019 | |
| Forte Bio-Pharma LLC | $5.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Manin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.